Johnson & Johnson (J&J), a company engaged in the production of medicines and medical equipment, is preparing to conduct an IPO of a division that produces consumer medical products. It is expected that on April 24, the company will begin meetings with potential investors within the framework of the road show (a complex of field events in the cities of the country, allowing to convey information about the product or services to the audience). J&J expects that the new company, which after the separation will be called Kenvue Inc., will receive a valuation close to $40 billion, and the IPO volume will be $3.5 billion. Kenvue shares are scheduled to be listed on the New York Stock Exchange under the ticker «KVUE». Recall that J&J announced plans to separate operations in the field of consumer medical products into an independent company in November 2021. The range of products produced by the division includes Neutrogena creams, Band-Aid patches, Listerine mouthwash, Tylenol paracetamol analog and Johnson's Baby series of products for children. In 2022, the division's revenue reached $14.95 billion, which accounted for about 15.7% of all J&J sales.
